Results 71 to 80 of about 338,185 (301)

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

Frontiers in Pharmacology, 2020
The COVID-19 pandemic represents an unprecedented challenge for the researchers to offer safe, tolerable, and effective treatment strategies for its causative agent known as SARS-CoV-2.
Chandan Sarkar, Milon Mondal, Muhammad Torequl Islam, Muhammad Torequl Islam, Miquel Martorell, Miquel Martorell, Anca Oana Docea, Alfred Maroyi, Javad Sharifi-Rad, Daniela Calina   +9 more
doaj   +1 more source

Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS

Frontiers in Pharmacology, 2022
Acute kidney injury (AKI) is a common complication among patients with the novel coronavirus (COVID-19). COVID-19 along with AKI usually resulted in a poor prognosis for those affected.
Bin Wu, Min Luo, Fengbo Wu, Zhiyao He, Yuwen Li, Ting Xu, Ting Xu   +6 more
doaj   +1 more source

Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome. [PDF]

, 2017
In the 50 years since acute respiratory distress syndrome (ARDS) was first described, substantial progress has been made in identifying the risk factors for and the pathogenic contributors to the syndrome and in characterising the protein expression ...
Calfee, Carolyn S, Meyer, Nuala J
core   +1 more source

Choosing drugs for UK COVID-19 treatment trials

Nature Reviews Drug Discovery, 2021
In 2020, the UK government funded a portfolio of platform trials to develop new treatments for COVID-19. A key feature was the independent prioritization of candidate drugs with central coordination to prevent duplication, accelerating recruitment to deliver definitive trial results.
Chinnery, PF, Bonnet, M, Cave, A, Hofer, MP, Lamb, A, McConkey, GA, Medcalf, N, Smith, SP, Tsakok, T, Watson, R, Webster, S, You, T   +11 more
openaire   +2 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Current therapeutic approaches to haemostasis correction in covid-19: a systematic review

Кубанский научный медицинский вестник, 2021
Background. The coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus has swept across countries worldwide. Despite an unprecedented volume of research, few drug therapies have been proved effective.
V. N. Antonov, M. V. Osikov, G. L. Ignatova, S. О. Zotov   +3 more
doaj   +1 more source

Equivalent Mid-Term Results of Open vs Endoscopic Gluteal Tendon Tear Repair Using Suture Anchors in Forty-Five Patients. [PDF]

, 2020
BackgroundLittle is known about the relative efficacy of open (OGR) vs endoscopic (EGR) gluteal tendon repair of gluteal tendon tears in minimizing pain and restoring function.
Bini, Stefano A, Jäger, Marcus, Maslaris, Alexander, Patel, Rina, Vail, Thomas P, Zhang, Alan L   +5 more
core  

Accelerated Progression of Gait Impairment in Parkinson's Disease and REM Sleep Without Atonia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective People with Parkinson's disease (PD) and rapid eye movement (REM) sleep without atonia (RSWA) often have more severe gait disturbances compared to PD without RSWA. The association between the presence and expression of RSWA and the rate of progression of gait impairment in PD is unknown.
Sommer L. Amundsen‐Huffmaster, Jae Woo Chung, Maria E. Linn‐Evans, Matthew N. Petrucci, Chiahao Lu, Destiny J. Weaver, Joshua De Kam, Scott E. Cooper, Paul J. Tuite, Aleksandar Videnovic, Michael J. Howell, Colum D. MacKinnon   +11 more
wiley   +1 more source

What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms

Virology Journal, 2023
Background Coronavirus disease 19 (COVID-19) is the disease caused by SARS-CoV-2, a highly infectious member of the coronavirus family, which emerged in December 2019 in “Wuhan, China”.
Sawsan Aboul-Fotouh, Ahmed Nageh Mahmoud, Esraa M. Elnahas, Mohamed Z. Habib, Sahar M. Abdelraouf   +4 more
doaj   +1 more source

SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review

Biomedicines, 2022
Sex differences identified in the COVID-19 pandemic are necessary to study. It is essential to investigate the efficacy of the drugs in clinical trials for the treatment of COVID-19, and to analyse the sex-related beneficial and adverse effects.
Donatas Stakišaitis, Linas Kapočius, Angelija Valančiūtė, Ingrida Balnytė, Tomas Tamošuitis, Arūnas Vaitkevičius, Kęstutis Sužiedėlis, Daiva Urbonienė, Vacis Tatarūnas, Evelina Kilimaitė, Dovydas Gečys, Vaiva Lesauskaitė   +11 more
doaj   +1 more source